Experimental immune therapy targets EBV-Linked cancers in early trial
NCT ID NCT05707910
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new immune-based treatment for people with advanced cancers linked to the Epstein-Barr virus (EBV) who have not responded to standard therapies. Only 6 participants are enrolled to check if the treatment is safe and to get a first look at whether it can shrink tumors. The goal is to control the disease, not to cure it.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EBV-POSITIVE ADVANCED MALIGNANT TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
West China Hospital
Chengdu, Sichuan, 610041, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New imaging agent could sharpen cancer detection
- New drug cocktail aims to stop Chemo-Linked nausea before it starts
- Could a painless electrical patch help cancer patients sleep better after surgery?
- Your tongue could reveal cancer: AI study analyzes 4,100 people
- New study aims to predict immunotherapy success in cancer patients
- Cancer combo therapy under the microscope: real-world study launched